methyl 6-(((benzyloxy)carbonyl)amino)hexanoate | 25580-87-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 6-(((benzyloxy)carbonyl)amino)hexanoate
• 英文别名: Methyl 6-([(benzyloxy)carbonyl]amino)hexanoate；methyl 6-(phenylmethoxycarbonylamino)hexanoate
• CAS: 25580-87-4
• 化学式: C₁₅H₂₁NO₄
• mdl: MFCD13683335
• 分子量: 279.336
• InChiKey: SQILAZKASNYAGB-UHFFFAOYSA-N

物化性质

• 沸点：
  411.1±38.0 °C(Predicted)
• 密度：
  1.101±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.466
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 6-(((benzyloxy)carbonyl)amino)hexanoate 生成 methyl 6-{[(benzyloxy)carbonyl]amino}-2-diazohexanoate
  参考文献：
  名称：

  Asymmetric catalysis of intramolecular N–H insertion reactions of α-diazocarbonyls

  摘要：

  Intramolecular N-H insertion reactions of alpha-diazocarbonyl substrates are catalysed by rhodium(II) carboxylates with catalyst-dependent competition with C-H insertion and beta-elimination; asymmetric N-H insertion leading to a pipecolic acid derivative with ee up to 45% is achieved using chiral catalysts.

  DOI：

  10.1039/cc9960001465
• 作为产物：
  描述：

  7-氨基-4-氯-3-甲氧基异香豆素 在 氯化亚砜 、 碳酸氢钠 作用下， 以 四氢呋喃 为溶剂， 生成 methyl 6-(((benzyloxy)carbonyl)amino)hexanoate
  参考文献：
  名称：

  Further characterization of a putative serine protease contributing to the γ-secretase cleavage of β-amyloid precursor protein

  摘要：

  The 3-alkoxy-7-amino-4-chloro-isocoumarins JLK-6 and JLK-2 have been shown to markedly reduce the production of Amyloid beta-peptide (A beta) by Amyloid-beta Precursor Protein (APP) expressing HEK293 cells by affecting the gamma-secretase cleavage of APP, with no effect on the cleavage of the Notch receptor. This suggested that these compounds do not directly inhibit the presenilin-dependent gamma-secretase complex but more likely interfere with an upstream target involved in gamma-secretase-associated pathway. The mechanism of action of these compounds is unknown and there are high fundamental and therapeutical interests to unravel their target. Isocoumarin compounds were previously shown to behave as potent mechanism-based irreversible inhibitors of serine proteases, suggesting that the JLK-directed target could belong to such enzyme family. To get further insight into structure-activity relationships and to develop more potent isocoumarin derivatives, we have synthesized and evaluated a series of isocoumarin analogues with modifications at positions 3, 4 and 7. In particular, the 7-amino group was substituted with either acyl, urethane, alkyl or aryl groups, which could represent additional interaction sites. Altogether, the results highlighted the essential integrity of the 3-alkoxy-7-amino-4-chloro-isocoumarin scaffold for A beta-lowering activity and supported the involvement of a seri ne protease, or may be more generally, a serine hydrolase. The newly reported 7-N-alkyl series produced the most active compounds with an IC50 between 10 and 30 mu M. Finally, we also explored peptide boronates, a series of reversible serine protease inhibitors, previously shown to also lower cellular A beta production. The presented data suggested they could act on the same target or interfere with the same pathway as isocoumarins derivatives. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.11.045

文献信息

• Aryl sulfonamides and sulfamide derivatives and uses thereof
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US06211241B1

  公开（公告）日：2001-04-03

  This invention is directed to novel aryl sulfonamide and sulfamide compounds which bind selectively to and inhibit the activity of the human Y5 receptor. This invention is also related to uses of these compounds for the treatment of feeding disorders such as obesity, anorexia nervosa, bulimia nervosa, and abnormal conditions such as sexual/reproductive disorders, depression, epileptic seizure, hypertension, cerebral hemorrhage, congestive heart failure or sleep disturbances and for the treatment of any disease in which antagonism of a Y5 receptor may be useful.

  这项发明涉及新型芳基磺酰胺和磺胺类化合物，其选择性地结合并抑制人Y5受体的活性。这项发明还涉及这些化合物用于治疗摄食障碍，如肥胖症、厌食症、暴食症，以及性/生殖障碍、抑郁症、癫痫发作、高血压、脑出血、充血性心力衰竭或睡眠障碍等异常情况，以及用于治疗任何可能需要Y5受体拮抗的疾病。
• Synthesis of nylon-like oligoamides
  作者：A. G. Cairns-Smith、R. Pettigrew

  DOI：10.1039/j39690001606

  日期：——

  We report syntheses of oligoamides that consist of oligomers of 6-aminohexanoic acid condensed with a central linear dicarboxylic acid or diamine.

  我们报道了由6-氨基己酸与中心线性二羧酸或二胺缩合的低聚物组成的低酰胺的合成。
• Trisubstituted amine compound
  申请人：Nakamura Yoshinori

  公开号：US20090023729A1

  公开（公告）日：2009-01-22

  The present invention relates to a compound of the general formula (1): wherein, Y is a methylene group, and the like; A is an optionally substituted heterocyclic group, and the like; B is an optionally substituted heterocyclic group, and the like; R 1 is an optionally substituted alkyl group, wherein the alkyl group further may optionally be substituted by an optionally substituted homocyclic group, and the like; and R 2 is an optionally substituted amino group, and the like; or a pharmaceutically acceptable derivative thereof, which has an inhibitory activity against cholesteryl ester transfer protein (CETP), thereby being useful for prophylaxis and/or treatment of arteriosclerotic diseases, hyperlipemia or dyslipidemia, and the like.

  本发明涉及一种通式（1）的化合物：其中，Y是亚甲基基团等；A是可选取的取代的杂环基团等；B是可选取的取代的杂环基团等；R1是可选取的取代的烷基团，其中该烷基团还可选择性地被可选取的取代的同环基团等所取代；而R2是可选取的取代的氨基团等；或其药学上可接受的衍生物，其具有对胆固醇酯转移蛋白（CETP）的抑制活性，因此可用于预防和/或治疗动脉硬化性疾病、高脂血症或血脂异常等。
• TRISUBSTITUTED AMINE COMPOUND
  申请人：NAKAMURA Yoshinori

  公开号：US20110092506A1

  公开（公告）日：2011-04-21

  The present invention relates to a compound of the general formula (1): wherein, Y is a methylene group, and the like; A is an optionally substituted heterocyclic group, and the like; B is an optionally substituted phenyl group, and the like; R 1 is an optionally substituted alkyl group, and the like; and R 2 is an optionally substituted amino group, and the like; or a pharmaceutically acceptable derivative thereof, which has an inhibitory activity against cholesteryl ester transfer protein (CETP), thereby being useful for prophylaxis and/or treatment of arteriosclerotic diseases, hyperlipemia or dyslipidemia, and the like.

  本发明涉及一种通式（1）的化合物：其中，Y是亚甲基基团等；A是可选取的取代杂环基团等；B是可选取的取代苯基团等；R1是可选取的取代烷基团等；R2是可选取的取代氨基团等；或其药学上可接受的衍生物。该化合物具有对胆固醇酯转移蛋白（CETP）的抑制活性，因此可用于预防和/或治疗动脉硬化性疾病、高脂血症或血脂异常等。
• Isonitriles as Alkyl Radical Precursors in Visible Light Mediated Hydro‐ and Deuterodeamination Reactions**
  作者：Irene Quirós、María Martín、Miguel Gomez‐Mendoza、María Jesús Cabrera‐Afonso、Marta Liras、Israel Fernández、Luis Nóvoa、Mariola Tortosa

  DOI：10.1002/anie.202317683

  日期：2024.2.12

  We report the use of isonitriles as alkyl radical precursors in visible-light mediated hydro- and deuterodeamination reactions. Most examples only require visible-light irradiation of the isonitrile in the presence of a silyl radical precursor, although a significant acceleration was observed in the presence of an organic photocatalyst. The method is scalable, shows broad functional group compatibility

  我们报道了在可见光介导的加氢和氘代脱氨基反应中使用异腈作为烷基自由基前体。大多数例子仅需要在甲硅烷基自由基前体存在下对异腈进行可见光照射，尽管在有机光催化剂存在下观察到显着的加速。该方法具有可扩展性，显示出广泛的官能团兼容性，并且适用于 C α伯、C α仲和 C α叔烷基异腈。